Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Thomasville National Bank

Thomasville National Bank decreased its stake in Pfizer Inc. (NYSE:PFE) by 10.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 81,014 shares of the biopharmaceutical company’s stock after selling 9,696 shares during the quarter. Thomasville National Bank’s holdings in Pfizer were worth $2,149,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Gladius Capital Management LP boosted its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP acquired a new position in shares of Pfizer in the 2nd quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the 3rd quarter worth about $35,000. Joseph Group Capital Management lifted its stake in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new stake in Pfizer in the 3rd quarter worth about $50,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.8 %

Shares of Pfizer stock traded down $0.22 during trading hours on Monday, hitting $26.50. The company’s stock had a trading volume of 11,581,401 shares, compared to its average volume of 32,019,525. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a 50 day moving average of $26.18 and a 200 day moving average of $28.04. The company has a market capitalization of $150.18 billion, a PE ratio of 35.81, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the company earned ($0.17) earnings per share. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Analyst Ratings Changes

PFE has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Guggenheim lowered their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.